专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012087004A2 USE OF UPR SIGNALING PATHWAY GENES IRE1 AND HXL1 FOR TREATMENT OF FUNGAL INFECTION AND MENINGITIS 审中-公开
标题翻译： UPR信号通路基因IRE1和HXL1在治疗真菌感染和脑膜炎中的应用
公开(公告)号：WO2012087004A2
公开(公告)日：2012-06-28
申请号：PCT/KR2011009862
申请日：2011-12-20
申请人： UNIV YONSEI IACF , UNIV CHUNG ANG IND , BAHN YONG SUN , JUNG KWANG WOO , KANG HYUN AH , CHEON SEON AH
发明人： BAHN YONG SUN , JUNG KWANG WOO , KANG HYUN AH , CHEON SEON AH
IPC分类号： G01N33/68 , A61P31/04 , C12Q1/68 , G01N33/15
CPC分类号： G01N33/5041 , A61K31/7088 , C07K14/4702 , C12N9/12 , C12N9/22 , C12N15/1137 , C12N2310/14 , C12Y301/26 , G01N2333/37 , G01N2500/10 , G01N2800/26 , G01N2800/28
摘要： The present invention relates to the use of the UPR signaling pathway genes IRE1 and HXL1 for treatment of fungal infection and meningitis. In the invention, it was newly found that disruption of Ire1 and Hxl1 (HAC1 and XBP1-Like gene 1) proteins, newly identified in Cryptococcus neoformans, genes encoding the proteins, provides an antifungal effect and a meningitis-treating effect. Based on this finding, a candidate which can show a synergistic effect when being co-administered with an existing antifungal agent or meningitis-treating agent can be screened and a novel pharmaceutical composition having an antifungal effect and a meningitis-treating effect can be provided.
摘要翻译：本发明涉及UPR信号传导途径基因IRE1和HXL1用于治疗真菌感染和脑膜炎的用途。在本发明中，新发现在新隐球菌新编码的编码蛋白质的基因Ire1和Hxl1（HAC1和XBP1-样基因1）蛋白质的破坏提供了抗真菌作用和脑膜炎治疗作用。基于该发现，可以筛选当与现有的抗真菌剂或脑膜炎治疗剂共同施用时能够显示协同效应的候选物，并且可以提供具有抗真菌作用和脑膜炎治疗效果的新型药物组合物。

2. 发明申请

WO2010079998A3 USE OF HOG, RAS, AND CAMP SIGNAL PATHWAY GENES FOR FUNGAL INFECTION TREATMENT 审中-公开
标题翻译： HOG，RAS和CAMP信号通路基因在真菌感染治疗中的应用
公开(公告)号：WO2010079998A3
公开(公告)日：2010-11-04
申请号：PCT/KR2010000137
申请日：2010-01-08
申请人： IND ACADEMIC COOP , BAHN YONG SUN , KO YOUNG JOON , MAENG SHIN AE , JUNG KWANG WOO , KIM GYU BUM
发明人： BAHN YONG SUN , KO YOUNG JOON , MAENG SHIN AE , JUNG KWANG WOO , KIM GYU BUM
IPC分类号： A61K38/02
CPC分类号： C12Q1/485 , C07K14/37 , C12N15/1072 , C12Q1/18 , G01N2333/37
摘要： The present invention provides a use of HOG, RAS, and CAMP signal pathway genes for a fungal infection treatment. Inventors of the present invention have studied the roles of SSK1, TCO2, SSK2, PBS2, HOG1, ENA1, and NHA1 genes in HOG pathway regulation of Cryptococcus neoformans, and found that the volume of biosynthesis of ergosterol increases when these genes are inhibited. As a great quantity of ergosterols are distributed on the cell membranes of fungi when these genes are inhibited, site of drug action of ergosterol-binding antifungal drugs increases, which significantly increases effects of ergosterol-binding antifungal drugs. Further, inventors of the present invention have studied the roles of RAS1, RAS2, CDC24, GPA1, CAC1, ACA1, PKA1, HSP12, and HSP122 genes in RAS and CAMP pathway regulation of Cryptococcus neoformans, and found that the susceptibility to polyene-based drugs or azole-based drugs increases when these genes are inhibited. Therefore, antifungal medical compositions containing inhibitors of the above-enumerated genes or proteins coded by the genes can be valuably used as superior complex antifungal agents that reduce the dosage of conventional antifungal agents and improve effects.
摘要翻译：本发明提供HOG，RAS和CAMP信号通路基因用于真菌感染治疗的用途。本发明的发明人已经研究了SSK1，TCO2，SSK2，PBS2，HOG1，ENA1和NHA1基因在新型隐球酵母的HOG通路调控中的作用，发现当这些基因被抑制时，麦角甾醇的生物合成量增加。由于大量的麦角甾醇分布在真菌的细胞膜上，当这些基因被抑制时，麦角甾醇结合的抗真菌药物的药物作用位点增加，这显着增加了麦角甾醇结合的抗真菌药物的作用。此外，本发明的发明人已经研究了RAS1，RAS2，CDC24，GPA1，CAC1，ACA1，PKA1，HSP12和HSP122基因在新生隐球菌的RAS和CAMP途径调控中的作用，发现对多烯类当这些基因被抑制时，药物或基于唑的药物会增加。因此，含有上述基因的抑制剂或由该基因编码的蛋白质的抗真菌医药组合物可以有价值地用作降低常规抗真菌剂剂量和改善效果的优异的复合抗真菌剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式